<DOC>
	<DOC>NCT00873210</DOC>
	<brief_summary>Objective of this study is to increase knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib.</brief_summary>
	<brief_title>Study In Patients With Kidney Cancer Treated With Sutent</brief_title>
	<detailed_description>Consecutive patients with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Consecutive patients with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy Hypersensitivity to sunitinib malate or to any of the excipients Any other contraindication to the use of sunitinib malate (based on decision of the treating physician).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>renal cell carcinoma</keyword>
	<keyword>sunitinib malate</keyword>
</DOC>